t
Trellus Health PLC announced the results of its Annual General Meeting, which was held on 30 June 2025. All 13 resolutions proposed to members were passed on a poll, with 11 resolutions passing as ordinary and 2 as special resolutions. As of 30 June 2025, the company had 161,508,333 ordinary shares in issue.
| Date | 1 Jul 2025 |
| Time | 07:00:08 |
| Category | AGMs and other meetings |
| ID | 0883P |
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Result of Annual General Meeting
The Annual General Meeting of Trellus Health plc was held at Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT on 30 June 2025 at 1:00 p.m. (UK time)
All 13 resolutions put to members were passed on a poll. Resolutions 1 to 11 were passed as ordinary resolutions and resolutions 12 and 13 were passed as special resolutions. The full text of the resolutions passed at the Annual General Meeting is set out in the Notice of Meeting, which is available on the Company's website at https://trellushealth.com/investors
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary)
|
27,025,398 |
99.9999 |
29 |
0.0001 |
643,426 |
|
Resolution 2 (Ordinary)
|
20,516,614 |
75.92 |
6,508,690 |
24.08 |
643,549 |
|
Resolution 3 (Ordinary)
|
26,767,828 |
99.92 |
20,253 |
0.08 |
880,772 |
|
Resolution 4 (Ordinary)
|
26,290,923 |
97.87 |
571,760 |
2.13 |
806,170 |
|
Resolution 5 (Ordinary)
|
26,766,798 |
99.64 |
95,762 |
0.36 |
806,293 |
|
Resolution 6 (Ordinary)
|
26,756,319 |
99.60 |
106,364 |
0.40 |
806,170 |
|
Resolution 7 (Ordinary)
|
20,506,319 |
76.34 |
6,356,364 |
23.66 |
806,170 |
|
Resolution 8 (Ordinary)
|
19,851,366 |
73.90 |
7,011,317 |
26.10 |
806,170 |
|
Resolution 9 (Ordinary)
|
26,942,921 |
99.69 |
82,506 |
0.31 |
643,426 |
|
Resolution 10 (Ordinary)
|
26,948,536 |
99.72 |
76,891 |
0.28 |
643,426 |
|
Resolution 11 (Ordinary)
|
26,767,808 |
99.67 |
89,875 |
0.33 |
811,170 |
|
Resolution 12 (Special)
|
26,756,053 |
99.71 |
77,649 |
0.29 |
835,151 |
|
Resolution 13 (Special)
|
26,771,655 |
99.66 |
90,905 |
0.34 |
806,293 |
The Board notes that Resolutions 2, 7 and 8 received a significant number of votes against those resolutions. In accordance with the QCA Corporate Governance Code, the Board remains committed to maintaining an open and transparent dialogue with shareholders and will continue to consult on any material issues of concern.
As at 30 June 2025, there were 161,508,333 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
|
Trellus Health plc |
|||
|
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder |
Via Walbrook PR |
||
|
Joy Bessenger, Chief Financial Officer |
|
||
|
|
|
||
|
Singer Capital Markets |
|
||
|
Jen Boorer / James Todd / Jalini Kalaravy |
Tel: +44 (0)20 7496 3000 |
||
|
|
|
||
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or [email protected] |
||
|
Paul McManus / Lianne Applegarth / |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/ |
||
|
Alice Woodings |
+44 (0)7407 804 654 |
||
About Trellus Health plc (www.trellushealth.com)
Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.
Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.
The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com